Skip to main content
Novacyt logo

Novacyt — Investor Relations & Filings

Ticker · ALNOV ISIN · FR0010397232 LEI · 213800BWAC2BF295EG28 PA Manufacturing
Open in API
Filings indexed 1,101 across all filing types
Latest filing 2023-09-01 Transaction in Own Shar…
Country FR France
Listing PA ALNOV

About Novacyt

https://novacyt.com/

Novacyt is an international molecular diagnostics company that provides a broad portfolio of integrated technologies and services. The company's core activities include the design, development, manufacturing, and commercialization of in vitro and molecular diagnostic tests, with a specialization in real-time PCR (qPCR) kits and reagents. Novacyt's solutions are applied across various markets, including clinical diagnostics for human health, with a focus on infectious diseases and oncology, as well as animal health and food safety. The company also offers custom development services, contract manufacturing, and pharmaceutical research services such as whole genome sequencing.

Recent filings

Filing Released Lang Actions
Information mensuelle sur le contrat de liquidite et sur le nombre total de droits de vote
Transaction in Own Shares Classification · 98% confidence The document is titled "Information mensuelle sur le contrat de liquidité et sur le nombre total de droits de vote" (Monthly information on the liquidity contract and the total number of voting rights). It details the activity under a liquidity contract (share buybacks/sales by the market maker, Invest Securities) for the period August 1 to August 31, 2023, and reports the total number of voting rights as of August 31, 2023. This type of regular, periodic disclosure concerning share transactions (often related to share buybacks or treasury stock management) and total voting rights is typically classified as a Transaction in Own Shares (POS) or sometimes a general Regulatory Filing (RNS). Since the core content focuses specifically on the execution of the share repurchase/liquidity agreement, POS is the most precise fit among the provided options. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K).
2023-09-01 French
Notice of rescheduled AGM
Report Publication Announcement Classification · 99% confidence The document is a short announcement (3898 characters) released via RNS (RNS Number : 3791K) titled "Notice of rescheduled AGM". It explicitly states that the Annual General Meeting ("AGM") will be held on 5 October 2023 and that further details will be provided to shareholders in due course. Because this document is an announcement about the AGM rather than the presentation materials or voting results themselves, and given its brevity and nature as a regulatory news service release, it fits best under the category for AGM-related announcements or general regulatory filings. Since 'AGM-R' is defined as 'Presentations and materials shared during the Annual General Meeting (AGM)', and this is merely a notice of the date, it is more accurately classified as a general regulatory announcement (RNS) or potentially a specific AGM notice if one existed. However, given the content is solely about scheduling the AGM, and it is not a DEF 14A (Proxy) or DVA (Voting Results), AGM-R is the most contextually relevant specific code, although RPA or RNS are also possibilities based on the 'Menu vs Meal' rule. Since it directly concerns the AGM, AGM-R is chosen as the primary subject matter, but the format suggests RNS or RPA. Given the explicit mention of 'AGM' and the short length, I will classify it as AGM-R as it pertains directly to the AGM event itself, even if it's just the notice.
2023-08-29 English
Avis de convocation à l’Assemblée Générale Annuelle reprogrammée
AGM Information Classification · 98% confidence The document is explicitly titled "Avis de convocation à l'Assemblée Générale Annuelle reprogrammée" (Notice of reconvened Annual General Meeting). It announces the date, time, and nature (virtual) of the upcoming Annual General Meeting (AGM) scheduled for October 5, 2023. This directly corresponds to the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM. Although it is a notice, the content is central to the AGM event itself, making AGM-R the most precise fit over a general RPA or RNS.
2023-08-29 French
Acquisition update
M&A Activity Classification · 99% confidence The document begins with 'RNS Number' and is dated August 17, 2023. It discusses an 'Acquisition update' regarding a recommended cash offer and notes that resolutions for a Court-sanctioned scheme of arrangement were passed at a Court Meeting and General Meeting. The text explicitly references the 'Yourgene's full announcement' and provides a link to it. The document concludes with standard disclaimers from 'RNS, the news service of the London Stock Exchange' and mentions that RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider. This structure—a brief update referencing another official announcement and originating from the RNS system—strongly indicates a general regulatory announcement rather than a comprehensive report (like 10-K or IR) or a specific event material (like AGM-R or IP). Since it is a general regulatory announcement that doesn't fit the highly specific categories (like DIRS, DIV, CAP, etc.), the most appropriate fallback category is Regulatory Filings (RNS). The document length (5744 chars) is moderate, but the content is purely informational about the status of a corporate action, typical of an RNS release.
2023-08-17 English
Acquisition update
AGM Information Classification · 99% confidence The document discusses an update regarding a recommended cash offer (Acquisition) by Novacyt UK Limited for Yourgene Health plc, effected by a Court-sanctioned scheme of arrangement. It specifically mentions that resolutions to approve the Scheme were passed at the Court Meeting and General Meeting held 'earlier today'. This relates to the formal results of a shareholder vote concerning a major corporate action (takeover/merger). While it references the Scheme Document (related to M&A/TAR), the core content is the announcement of the successful shareholder vote outcome for the scheme. This aligns best with the Declaration of Voting Results & Voting Rights Announcements (DVA), as it confirms the outcome of shareholder votes required for the transaction to proceed. It is not the M&A announcement itself (TAR), but the result of the required shareholder approval process.
2023-08-17 English
Liquidity Agreement and Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement released via RNS (RNS Number: 9330H) on August 1, 2023. The content explicitly details a 'Liquidity Agreement Monthly Update' concerning share purchases/sales under that agreement, and provides the 'Total Voting Rights' figure (70,626,248 ordinary shares). Updates on liquidity agreements and total voting rights are specific disclosures often required by listing rules, but they do not fit neatly into the primary financial reports (10-K, IR) or specific corporate actions like dividends (DIV) or capital changes (CAP/SHA). Since it is a formal, periodic regulatory update that doesn't match a more specific category (like DIRS, DIV, or ER), it falls best under the general 'Regulatory Filings' category (RNS) as a miscellaneous regulatory announcement.
2023-08-01 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.